Consumer medicine information

Ongentys

Opicapone

BRAND INFORMATION

Brand name

Ongentys

Active ingredient

Opicapone

Schedule

S4

 

Consumer medicine information (CMI) leaflet

Please read this leaflet carefully before you start using Ongentys.

SUMMARY CMI

ONGENTYS

Consumer Medicine Information (CMI) summary

The full CMI on the next page has more details. If you are worried about using this medicine, speak to your doctor or pharmacist.

 This medicine is new or being used differently. Please report side effects. See the full CMI for further details.

1. Why am I using ONGENTYS?

ONGENTYS contains the active ingredient opicapone. ONGENTYS is used to treat symptoms of Parkinson's disease. Parkinson's disease is a progressive disease of the nervous system that causes shaking and affects your movement.

For more information, see Section 1. Why am I using ONGENTYS? in the full CMI.

2. What should I know before I use ONGENTYS?

Do not use if you have ever had an allergic reaction to opicapone or any of the ingredients listed in Section 7. Product details in the full CMI.

Talk to your doctor if you have any other medical conditions, take any other medicines, or are pregnant or plan to become pregnant or are breastfeeding.

For more information, see Section 2. What should I know before I use ONGENTYS? in the full CMI.

3. What if I am taking other medicines?

Some medicines may interfere with ONGENTYS and affect how it works.

A list of these medicines is in Section 3. What if I am taking other medicines? in the full CMI.

4. How do I use ONGENTYS?

  • Take one 50 mg capsule of ONGENTYS once daily or as directed by your doctor.
  • Swallow the capsule whole with a glass of water. Take the capsule preferably on an empty stomach (i.e. two hours before or two hours after a meal) and at least one hour before or after taking your levodopa medicine.

More instructions can be found in Section 4. How do I use ONGENTYS? in the full CMI.

5. What should I know while using ONGENTYS?

Things you should do
  • Remind any doctor, dentist or pharmacist who treat you that you are using ONGENTYS.
  • If you are going to have surgery, tell the surgeon or anaesthetist that you are taking this medicine.
  • If you are pregnant, think you may be pregnant or are planning to have a baby while taking this medicine, tell your doctor immediately.
  • If you are about to have any blood tests, tell your doctor that you are taking this medicine.
Things you should not do
  • Do not take ONGENTYS to treat any other complaints unless your doctor tells you to.
  • Do not stop taking your medicine or lower the dosage without checking with your doctor.
  • Do not give your medicine to anyone else, even if they have the same condition as you.
Driving or using machines
  • ONGENTYS taken with levodopa may make you feel light-headed, dizzy, or sleepy. Do not drive or operate machinery if you experience any of these side effects.
Looking after your medicine
  • Store below 30°C. Store in the original package in order to protect from moisture.

For more information, see Section 5. What should I know while using ONGENTYS? in the full CMI.

6. Are there any side effects?

The most common side effects are involuntary and uncontrollable, difficult or painful body movements. Serious side effects include hallucinations, shortness of breath, fainting and increased levels of the enzyme (creatine kinase) in your blood. Many of these side effects can be managed by your doctor adjusting your other medicines.

For more information, including what to do if you have any side effects, see Section 6. Are there any side effects? in the full CMI.

 This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems.



FULL CMI

ONGENTYS

Active ingredient(s): opicapone (o-pic-a-pone)


Consumer Medicine Information (CMI)

This leaflet provides important information about using ONGENTYS. You should also speak to your doctor or pharmacist if you would like further information or if you have any concerns or questions about using ONGENTYS.

Where to find information in this leaflet:

1. Why am I using ONGENTYS?
2. What should I know before I use ONGENTYS?
3. What if I am taking other medicines?
4. How do I use ONGENTYS?
5. What should I know while using ONGENTYS?
6. Are there any side effects?
7. Product details

1. Why am I using ONGENTYS?

This medicine is used to treat symptoms of Parkinson's disease and associated movement problems. Parkinson's disease is a progressive disease of the nervous system that causes shaking and affects your movement.

ONGENTYS is for use in adults who are already taking medicines containing levodopa and DOPA decarboxylase inhibitors. It increases the effects of levodopa and helps to relieve the symptoms of Parkinson's disease and movement problems.

Opicapone belongs to a group of medicines called antiparkinsonian/other dopaminergic agents.

Opicapone works to restore the levels of dopamine in the areas of the brain that control movement and coordination. It enhances the effects of another drug, levodopa, commonly used to treat Parkinson's Disease. Opicapone blocks an enzyme that is involved in the breakdown of levodopa in the body, called catechol-O-methyl transferase (COMT). As a result, levodopa remains active for longer time.

Ask your doctor if you have any questions about why this medicine has been prescribed for you.

Your doctor may have prescribed it for another reason.

This medicine is not addictive.

This medicine is available only with a doctor's prescription.

2. What should I know before I use ONGENTYS?

Warnings

Do not take ONGENTYS if you have an allergy to:

  • opicapone, or any of the ingredients listed at the end of this leaflet under Section 7. Product details.
  • any other similar medicines

Some of the symptoms of an allergic reaction may include:

  • shortness of breath
  • wheezing or difficulty breathing
  • swelling of the face, lips, tongue or other parts of the body
  • rash, itching or hives on the skin

Always check the ingredients to make sure you can use this medicine.

Do not take ONGENTYS if:

  • you have a tumour of the adrenal gland (known as phaeochromocytoma), or of the nervous system (known as paraganglioma), or any other tumour which increase the risk of severe high blood pressure
  • you have ever suffered from neuroleptic malignant syndrome which is a rare reaction to antipsychotic medicines;
  • you have ever suffered from a rare muscle disorder called rhabdomyolysis which was not caused by injury;
  • you are taking certain antidepressants called monoamine-oxidase (MAO) inhibitors (e.g. phenelzine, tranylcypromine or moclobemide). Ask your doctor or pharmacist if you can take your antidepressant together with ONGENTYS; and
  • you are taking linezolide (an antibiotic for the treatment of infections, particularly severe or complicated).

Pregnancy and breastfeeding

Check with your doctor if you are pregnant or intend to become pregnant.

Ongentys is not recommended if you are pregnant. You should use effective contraception if it is possible that you might become pregnant.

Talk to your doctor if you are breastfeeding or intend to breastfeed.

It is not known if ONGENTYS passes into human breast milk. As the risk to babies/infants cannot be excluded you must stop breastfeeding while taking ONGENTYS.

Do not give this medicine to a child or adolescent under the age of 18 years.

Safety and effectiveness in children younger than 18 years have not been established.

Do not take this medicine after the expiry date printed on the pack or if the packaging is torn or shows signs of tampering.

If it has expired or is damaged, return it to your pharmacist for disposal.

If you are not sure whether you should start taking this medicine, talk to your doctor.

Before you start to take ONGENTYS:

Tell your doctor if you have allergies to any other medicines, foods, preservatives or dyes.

Tell your doctor if you have or have had any of the following medical conditions:

  • liver problems
  • suffer from loss of appetite, or weight loss
  • feel weakness, or exhaustion within a short period of time.

Your doctor may need to reconsider your treatment.

Tell your doctor if:

You or your family/carer notices you are developing urges or cravings to behave in ways that are unusual for you or you cannot resist the impulse, drive or temptation to carry out certain activities that could harm you or others. These behaviours are called ‘impulse control disorders’ and can include: addictive gambling, an abnormally high sex drive or an increased preoccupation with sexual thoughts or feelings. Behaviours such as these have been reported in patients using other medicines for Parkinsons´s disease.

Your doctor may need to review your treatments.

ONGENTYS contains lactose. If you have been told by your doctor that you have intolerance to some sugars, tell your doctor before taking it.

ONGENTYS contains residues of sulfites which may rarely cause severe hypersensitivity reactions and bronchospasm.

ONGENTYS contains less than 1 mmol sodium (23 mg) per capsule, that is to say essentially ‘sodium-free’.

If you have not told your doctor about any of the above, tell him/her before you start taking ONGENTYS.

3. What if I am taking other medicines?

Tell your doctor or pharmacist if you are taking any other medicines, including any medicines, vitamins or supplements that you buy without a prescription from your pharmacy, supermarket or health food shop.

ONGENTYS will be administered with other medicines containing levodopa and DOPA decarboxylase inhibitors.

Read the notice of these medicines carefully.

Some medicines and ONGENTYS may interfere with each other. These include:

  • medicines for depression or anxiety such as venlafaxine, maprotiline or desipramine. Taking ONGENTYS with these medicines may increase the risk of side effects. Your doctor may need to adjust your treatment;
  • Safinamide used for Parkinson's disease. There is no experience taking ONGENTYS and safinamide together. Your doctor may need to adjust your treatment;
  • medicines to treat asthma such as rimiterole or isoprenaline. ONGENTYS may increase their effect;
  • medicines used to treat allergic reactions such as adrenaline. ONGENTYS may increase their effect;
  • medicines used to treat heart failure such as dobutamine, dopamine or dopexamine. ONGENTYS may increase their effects;
  • medicines containing quinidine, a medicine used to treat abnormal heart rhythms or malaria. Taking ONGENTYS and quinidine together, i.e. at the same time, may decrease the effect of ONGENTYS.
  • medicines containing warfarin, a medicine used to thin the blood. ONGENTYS may reduce the plasma levels of warfarin.

These medicines may be affected by ONGENTYS or may affect how well it works. You may need different amounts of your medicines, or you may need to take different medicines.

Your doctor and pharmacist have more information on medicines to be careful with or avoid while taking this medicine.

4. How do I use ONGENTYS?

Follow all directions given to you by your doctor or pharmacist carefully.

They may differ from the information contained in this leaflet.

If you do not understand the instructions, ask your doctor or pharmacist for help.

How much to take

The recommended dose is 50 mg once daily. Your doctor may have prescribed a different dose.

Ask your doctor or pharmacist if you are unsure of the correct dose for you.

They will tell you exactly how much to take.

Follow the instructions they give you.

If you take the wrong dose, ONGENTYS may not work as well and your problem may not improve.

How to take ONGENTYS

ONGENTYS is for oral use.

Take ONGENTYS at least one hour before or after taking your levodopa medicine.

Swallow the capsule whole with a glass of water. ONGENTYS shall be taken preferably on an empty stomach (i.e. two hours before or two hours after a meal).

Do not change the prescribed dose on your own. Talk to your doctor or pharmacist if you think the effect of this medicine is too low or too strong.

The dose of other medicines to treat Parkinson's disease may need to be adjusted when you start taking ONGENTYS. Follow the instructions that your doctor has given you

When to take ONGENTYS

Take ONGENTYS preferably at bedtime.

How long to take ONGENTYS

Continue taking your medicine for as long as your doctor tells you.

This medicine helps to control your condition, but does not cure it. It is important to keep taking your medicine even if you feel well.

Do not stop taking ONGENTYS unless your doctor tells you to as your symptoms may get worse.

If you stop taking ONGENTYS your doctor may need to adjust the dose of other medicines that you are taking to treat Parkinson's disease.

If you have any further questions on the use of this medicine, ask your doctor or pharmacist.

If you forget to take ONGENTYS

If you forget to take one dose, you should continue the treatment and take the next dose as scheduled.

Do not take a double dose to make up for the dose that you missed.

If you are not sure what to do, ask your doctor or pharmacist.

If you have trouble remembering to take your medicine, ask your pharmacist for some hints.

If you take too much ONGENTYS (overdose)

Immediately telephone your doctor or the Poisons Information Centre (telephone Australia 13 11 26) for advice or go to Accident and Emergency at the nearest hospital, if you think that you or anyone else may have taken too much ONGENTYS. Do this even if there are no signs of discomfort or poisoning.

You may need urgent medical attention.

Take the medicine package and this leaflet with you. This will help the doctor identify what you have taken.

5. What should I know while using ONGENTYS?

Things you should do

If you are about to be started on any new medicine, remind your doctor and pharmacist that you are taking ONGENTYS.

Tell any other doctors, dentists and pharmacists who treat you that you are taking this medicine.

If you are going to have surgery, tell the surgeon or anaesthetist that you are taking this medicine. It may affect other medicines used during surgery.

If you are about to have any blood tests, tell your doctor that you are taking this medicine. It may interfere with the results of some tests.

Keep all of your doctor's appointments so that your progress can be checked. Your doctor may do some tests from time to time to make sure the medicine is working and to prevent unwanted side effects.

Things you should not do

Do not take ONGENTYS to treat any other complaints unless your doctor tells you to.

Do not give your medicine to anyone else, even if they have the same condition as you.

Do not stop taking your medicine or lower the dosage without checking with your doctor.

Your doctor may want you to gradually reduce the amount you are taking before stopping completely.

Things to be careful of

Be careful driving or operating machinery until you know how ONGENTYS affects you.

This medicine may influence reactions, and the ability to drive and use tools or machines. ONGENTYS taken with levodopa may make you feel light-headed, dizzy, or sleepy.

Do not drive or operate machinery if you experience any of these side effects.

If you feel light-headed, dizzy or faint when getting out of bed or standing up, get up slowly.

Standing up slowly, especially when you get up from bed or chairs, will help your body get used to the change in position and blood pressure. If this problem continues or gets worse, talk to your doctor.

Looking after your medicine

Store in the original package to protect from moisture.

If you take the capsules out of the blister pack, they may not keep well.

Keep your medicine in a cool dry place where the temperature stays below 30°C.

Do not store ONGENTYS or any other medicine in the bathroom or near a sink. Do not leave it on a window sill or in the car. Heat and dampness can destroy some medicines.

Keep it where children cannot reach it. A locked cupboard at least one-and-a-half meters above the ground is a good place to store medicines.

Getting rid of any unwanted medicine

If your doctor tells you to stop taking this medicine or the expiry date has passed, ask your pharmacist what to do with any medicine that is left over.

6. Are there any side effects?

Tell your doctor or pharmacist as soon as possible if you do not feel well while you are taking ONGENTYS.

All medicines can have side effects. Sometimes they are serious, most of the time they are not. You may need medical attention if you get some of the side effects.

Side effects caused by ONGENTYS are usually mild to moderate and occur mostly within the first five weeks of treatment. Some side effects may be caused by the increased effects of using ONGENTYS together with levodopa. Many of the side effects can be managed by your doctor adjusting your levodopa medicine.

It is very common to experience involuntary and uncontrollable, or difficult or painful body movements when taking ONGENTYS.

Do not be alarmed by the following lists of side effects. You may not experience any of them.

Ask your doctor or pharmacist to answer any questions you may have.

Less serious side effects

Less serious side effectsWhat to do
General well-being related
  • difficulty falling or staying asleep
  • sleepiness
  • sleep disorder
  • high or low blood pressure
  • dry mouth
  • urinary tract infection
  • weight loss
  • loss of appetite
  • strange dreams
  • feeling low in energy or tired
  • having falls
  • difficulty in concentration
Coordination related
  • feeling unsteady
  • shaking
  • dizziness
  • involuntary and uncontrollable, excessive, difficult or painful body movements
Other symptoms
  • increased levels of triglycerides (fats) in your blood
  • increased levels of the enzyme (creatine kinase) in your blood
  • depression
  • anxiety
  • nightmares
  • headache
  • dry eye
  • blocked ear
  • a fall in blood pressure on standing up which causes dizziness, light-headedness or fainting
  • pain or swelling of the abdomen
  • abnormal colour of urine
  • need to wake and pass urine at night
Stomach/digestion related
  • constipation
  • feeling sick (nausea)
  • vomiting (being sick)
  • diarrhoea
  • indigestion
Pain related
  • muscle spasm
  • muscle twitching, stiffness, or pain
  • pain in arms or legs
Speak to your doctor or pharmacist if you have any of these less serious side effects and they worry you.

Serious side effects

Serious side effectsWhat to do
General well-being related
  • experiencing, seeing or hearing things which do not exist (hallucinations)
  • shortness of breath
  • fainting
Coordination related
  • Parkinson's disease
Tell your doctor as soon as possible if you notice any of these serious side effects.

Tell your doctor or pharmacist if you notice anything else that is making you feel unwell. Other side effects not listed above may also occur in some people.

Some of these side effects (e.g. increased levels of triglycerides or the enzyme creatine kinase in your blood, or high or low blood pressure) can only be found when your doctor does tests from time to time to check your progress.

Ischemic heart disease (diseases of the arteries with insufficient blood supply to the heart) have been frequently observed when using other substances with the same mechanism of action as opicapone (inhibition of COMT).

Reporting side effects

After you have received medical advice for any side effects you experience, you can report side effects to the Therapeutic Goods Administration online at www.tga.gov.au/reporting-problems. By reporting side effects, you can help provide more information on the safety of this medicine.

Always make sure you speak to your doctor or pharmacist before you decide to stop taking any of your medicines.

7. Product details

This medicine is only available with a doctor's prescription.

What ONGENTYS contains

Active ingredient
(main ingredient)
Each ONGENTYS capsule contains 50 mg opicapone
Other ingredients
(inactive ingredients)
  • lactose monohydrate
  • sodium starch glycollate type A
  • pregelatinised maize starch
  • magnesium stearate
  • gelatin
  • indigo carmine aluminium lake
  • erythrosine
  • titanium dioxide
  • shellac
  • propylene glycol
  • ammonia solution, concentrated
  • simethicone

Do not take this medicine if you are allergic to any of these ingredients.

What ONGENTYS looks like

ONGENTYS 50 mg hard capsules are dark blue, imprinted “OPC 50” on the cap and “Bial” on the body.

Each ONGENTYS 50 mg hard capsules pack contains 10, 30 or 90 capsules (AUST R 321017).

Not all pack sizes may be marketed.

Who distributes ONGENTYS

Manufacturer

BIAL - Portela & Cª, S.A.
À Av. da Siderurgia Nacional
4745-457 S. Mamede do Coronado
Portugal

Sponsor

Maxx Pharma Pty Ltd
Level 20, 181 William Street
Melbourne, VIC, 3000
Australia

This leaflet was revised in September 2022.

Published by MIMS January 2023

BRAND INFORMATION

Brand name

Ongentys

Active ingredient

Opicapone

Schedule

S4

 

1 Name of Medicine

Opicapone.

2 Qualitative and Quantitative Composition

Each hard capsule contains 50 mg of opicapone as active substance.

Excipients with known effect.

Each hard capsule contains 156 mg of lactose monohydrate and approximately 76 mg of gelatine which contains sulfites as a residue.
For the full list of excipients, see Section 6.1 List of Excipients.

3 Pharmaceutical Form

Hard capsules.

Dark blue capsules, size 1 (approximately 19 mm) imprinted "OPC 50" on the cap and "Bial" on the body.

4 Clinical Particulars

4.1 Therapeutic Indications

Ongentys is indicated as adjunctive therapy to preparations of levodopa/DOPA decarboxylase inhibitors (DDCI) in adult patients with Parkinson's disease and end-of-dose motor fluctuations who cannot be stabilised on those combinations.

4.2 Dose and Method of Administration

Dosage.

The recommended dose of opicapone is 50 mg.
Ongentys should be taken once daily at bedtime, preferably without food, at least one hour before or after levodopa combinations.

Missed dose.

If one dose is missed, the next dose should be taken as scheduled. The patient should not take an extra dose to make up for the missed dose.

Method of administration.

Oral use.
The capsules should be swallowed whole with water. Ongentys shall be taken preferably on an empty stomach (that is two hours before or two hours after a meal).

Dosage adjustment.

Antiparkinsonian therapy.

Ongentys is to be administered as an adjunct to levodopa treatment and enhances the effects of levodopa. Hence, it is often necessary to adjust levodopa dose by extending the dosing intervals and/or reducing the amount of levodopa per dose within the first days to first weeks after initiating the treatment with opicapone according to the clinical condition of the patient (see Section 4.4 Special Warnings and Precautions for Use).

Renal impairment.

No dose adjustment is necessary in patients with renal impairment, as opicapone is not primarily excreted by the kidney (see Section 5.2 Pharmacokinetic Properties).

Hepatic impairment.

Ongentys is not recommended in patients with hepatic impairment or hepatic cirrhosis (Child-Pugh Class A, B, C).
The bioavailability of opicapone was significantly higher in patients with moderate chronic hepatic impairment (see Section 5.2 Pharmacokinetic Properties).
There is no clinical experience in patients with mild hepatic impairment (Child-Pugh Class A), and in patients with severe hepatic impairment (Child-Pugh Class C).

Paediatric population.

There is no relevant use of Ongentys in the paediatric population with Parkinson's disease and motor fluctuations.

Elderly.

No dose adjustment is needed for elderly patients (see Section 5.2 Pharmacokinetic Properties). Caution must be exercised in patients ≥ 75 years of age as there is limited experience in this age group.

4.3 Contraindications

Hypersensitivity to the active substance or to any of the excipients listed in Section 6.1 List of Excipients.
Phaeochromocytoma, paraganglioma, or other catecholamine secreting neoplasms.
History of neuroleptic malignant syndrome and/or non-traumatic rhabdomyolysis.
Concomitant use with monoamine oxidase (MAO-A and MAO-B) inhibitors (e.g. phenelzine, tranylcypromine and moclobemide) other than those for the treatment of Parkinson's disease (see Section 4.5 Interactions with Other Medicines and Other Forms of Interactions).

4.4 Special Warnings and Precautions for Use

Dose adjustments of antiparkinsonian therapy.

Ongentys is to be administered as an adjunct to levodopa treatment. Hence, the precautions valid for levodopa treatment should also be taken into account for Ongentys. Opicapone enhances the effects of levodopa. To reduce levodopa-related dopaminergic adverse reactions (e.g. dyskinesia, hallucinations, nausea, vomiting and orthostatic hypotension), it is often necessary to adjust the daily dose of levodopa by extending the dosing intervals and/or reducing the amount of levodopa per dose within the first days to first weeks after initiating treatment with Ongentys, according to the clinical condition of the patient (see Section 4.2 Dose and Method of Administration).
There is limited data available regarding the pharmacokinetic effects of Ongentys on sustained release formulation of levodopa. Thus, appropriate caution is advised.
If Ongentys is discontinued it is necessary to adjust the dosing of the other antiparkinsonian treatments, especially levodopa, to achieve a sufficient level of control of the symptoms.

Psychiatric disorders.

Patients and caregivers should be made aware that impulse control disorders including pathological gambling, increased libido, hypersexuality, compulsive spending or buying, binge eating and compulsive eating can occur in patients treated with dopamine agonists and/or other dopaminergic treatments. Patients should be monitored regularly for the development of impulse control disorders and review of treatment is recommended if such symptoms develop.

Others.

Increases in liver enzymes were reported in studies with nitrocatechol inhibitors of catechol-O-methyltransferase (COMT). For patients who experience progressive anorexia, asthenia and weight decrease within a relatively short period of time, a general medical evaluation including liver function should be considered.
Ischemic heart diseases were frequently observed in case of use of other substances having the same mechanism of action as opicapone (COMT inhibition).

Excipients.

Ongentys contains lactose. Patients with rare hereditary problems of galactose intolerance, the total lactase deficiency or glucose-galactose malabsorption should not take this medicinal product.
Ongentys contains less than 1 mmol sodium (23 mg) per capsule, that is to say essentially 'sodium-free'.

Use in the elderly.

Caution must be exercised in patients ≥ 75 years of age as there is limited experience in this age group (see Section 4.2 Dose and Method of Administration).

Paediatric use.

No data available.

Effects on laboratory tests.

No data available.

4.5 Interactions with Other Medicines and Other Forms of Interactions

Monoamino oxidase (MAO) inhibitors.

Combination of opicapone and MAO inhibitors could result in inhibition of the majority of the pathways responsible for the metabolism of catecholamines. Because of this, concomitant use of opicapone with MAO inhibitors (e.g. phenelzine, tranylcypromine, linezolid and moclobemide) other than those for the treatment of Parkinson's disease is contraindicated (see Section 4.3 Contraindications).
Concomitant use of opicapone and MAO inhibitors for the treatment of Parkinson's disease, e.g. rasagiline (up to 1 mg/day) and selegiline (up to 10 mg/day in oral formulation or 1.25 mg/day in buccal absorption formulation), is permissible.
There is no experience with opicapone when used concomitantly with the MAO-B inhibitor safinamide. Therefore, their concomitant use should be considered with appropriate caution.

Medicinal products metabolised by COMT.

Opicapone may interfere with the metabolism of medicinal products containing a catechol group that are metabolised by COMT (e.g. rimiterol hydrobromide, isoprenaline, adrenaline (epinephrine), noradrenaline (norepinephrine), dopamine, dopexamine or dobutamine) leading to potentiated effects of these medicinal products. Careful monitoring of patients being treated with these medicinal products is advised when opicapone is used.

Tricyclic antidepressants and noradrenaline (norepinephrine) re-uptake inhibitors.

There is limited experience with opicapone when used concomitantly with tricyclic antidepressants and noradrenaline (norepinephrine) re-uptake inhibitors (e.g. venlafaxine, maprotiline and desipramine). Thus, their concomitant use should be considered with appropriate caution.

Hormonal contraceptives.

The potential for drug interactions between opicapone and hormonal contraceptives had not been assessed. Female patients on oral contraceptives, while on treatment with opicapone should be informed that additional non-hormonal methods of contraception are to be used.

Influence of opicapone over other substances.

Warfarin.

After the co-administration of multiple doses of 50 mg of opicapone QD and a single dose of 25 mg of warfarin, the Cmax of warfarin S and R (CYP2C9, 3A4 end 1A2 substrates) remained unchanged. A reduction of 13.7% and 14.8% of the - AUC of warfarin S and R (respectively) was observed in the presence of opicapone.

CYP2C8 and OATP1B1 substrates.

Opicapone is a weak inhibitor of CYP2C8 (with an estimated Ki of 0.9 microgram/mL) and of OATP1B1, under in vitro testing.
A clinical study conducted in healthy subjects showed that there were no significant changes in the total plasma exposure of repaglinide, a CYP2C8 and OATP1B1 substrate, when administered concomitantly with opicapone 50 mg, following repeated once-daily administration.

In vitro studies.

In in vitro studies in human hepatic microsomes, minor inhibition of CYP1A2 and CYP2B6 was observed. All reductions in activity essentially occurred at the highest concentration of opicapone (10 microgram/mL).
Opicapone inhibited CYP2C8 activity with an estimated Ki of 0.9 microgram/mL.
Opicapone reduced CYP2C9 activity through competitive/ mixed type mode of inhibition.
Opicapone and/or BIA 9-1103 inhibits OAT1, OAT3, OATP1B1, OATP1B3 and BSEP in vitro.
Considering the plasma free fractions of opicapone and BIA 9-1103 detected in clinical studies, no interaction is expected in OAT1, OAT3, OATP1B1, OATP1B3, OCT1, OCT2, BCRP, P-gp/MDR1, BSEP, MATE1 and MATE2-K transporters. Inhibition of OATP1B1 cannot be ruled out.

Influence of other substances over opicapone.

In vitro studies have shown that opicapone is not transported by OATP1B1, but is transported by OATP1B3, and efflux transported by P-gp and BCRP. BIA 9-1103, its major metabolite, was transported by OATP1B1 and OATP1B3, and efflux transported by BCRP, but is not a substrate for the P-gp/MDR1 efflux transporter.
The effects of the inhibitors of OATP1B3, Pgp or BCRP on the pharmacokinetics of OPC and BIA 9-1103 were not studied.

Quinidine.

A study conducted in healthy volunteers showed that when a single dose of 50 mg opicapone was co-administered (within 1 hour) with a single dose of quinidine (600 mg), systemic exposure of opicapone decreased by 37% AUC0-tlast and 30% Cmax. Thus, particular consideration should be given to cases where quinidine needs to be administered together with opicapone as their co-administration should be avoided.

4.6 Fertility, Pregnancy and Lactation

Effects on fertility.

The effects of opicapone on fertility in humans have not been studied.
In rats, opicapone did not affect male and female fertility or prenatal development at exposure levels 16-17 times the therapeutic exposure in humans.
(Category B2)
There are no or limited amount of data from the use of opicapone in pregnant women. Opicapone and/or its metabolites crossed the placenta in rats. Animal studies are insufficient with respect to reproductive toxicity. Ongentys is not recommended during pregnancy and in women of childbearing potential not using contraception.
In rats opicapone was not teratogenic at oral doses up to 1000 mg/kg/day (exposure levels 31 times the therapeutic exposure in humans). In pregnant rabbits, opicapone was less well tolerated resulting in maximum systemic exposure levels around or below the therapeutic range. Although embryo-fetal development was not negatively influenced in rabbits, the study is not considered predictive for human risk assessment. During studies on pre- and post-natal development in rats, no adverse effect was observed on the F0 generation at oral doses up to 1000 mg/kg/day, corresponding to a safety margin of 31 times the therapeutic exposure in humans.
Levels of opicapone-related material in the milk of lactating rats were equivalent to those in plasma. It is unknown whether opicapone or its metabolites are excreted into human milk. A risk to the newborns/infants cannot be excluded. Breast-feeding should be discontinued during treatment with Ongentys.

4.7 Effects on Ability to Drive and Use Machines

Opicapone in association with levodopa may have major influence on the ability to drive and use machines. Opicapone may, together with levodopa, cause dizziness, symptomatic orthostatism and somnolence. Therefore, caution should be exercised when driving or using machines.

4.8 Adverse Effects (Undesirable Effects)

Summary of the safety profile.

The safety of opicapone was evaluated in two Phase 3 double-blind, placebo and active controlled studies in 1,027 randomized adult patients with Parkinson's disease treated with levodopa/DDCI (alone or in combination with other antiparkinsonian drugs) and end-of-dose motor fluctuations for up to 15 weeks. At screening, the mean age was similar in all treatment groups in both studies, ranging between 61.5 and 65.3 years.

Common adverse reactions.

Adverse reactions that occurred in the pooled controlled trials at an incidence of at least 3% in any treatment group and greater than placebo is presented in Table 1. The most common adverse reactions (incidence at least 4% in total OPC) were dyskinesia, constipation, insomnia, dry mouth.

Other adverse reactions.

Opicapone use compared with placebo was also associated with slightly higher frequencies of the following adverse reactions:
Adverse reactions are presented by System Organ Class and frequency. Frequency are indicated in a descending order defined as follows: very common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1,000 to < 1/100), rare (≥ 1/10,000 to < 1/1,000), very rare (< 1/10,000), not known (cannot be estimated from the available data).
Within each category of frequency, the adverse reactions are indicated by descending order of severity.

Metabolism and nutrition disorders.

Uncommon: hypertriglyceridemia, decreased appetite.

Psychiatric disorders.

Common: hallucination, hallucination visual, abnormal dreams.
Uncommon: hallucination auditory, depression, anxiety, nightmare, sleep disorder.

Nervous system disorders.

Common: headache.
Uncommon: syncope, hyperkinesia, dysgeusia.

Eye disorders.

Uncommon: dry eye.

Ear and labyrinth disorders.

Uncommon: ear congestion.

Vascular disorders.

Common: orthostatic hypotension.
Uncommon: hypotension.

Respiratory, thoracic and mediastinal disorders.

Uncommon: dyspnoea.

Gastrointestinal disorders.

Common: vomiting.
Uncommon: abdominal pain, abdominal pain upper, dyspepsia, abdominal distention.

Musculoskeletal and connective tissue disorders.

Common: muscle spasms.
Uncommon: muscle twitching, musculoskeletal stiffness, myalgia, pain in extremities.

Renal and urinary disorders.

Uncommon: chromaturia, nocturia.

Adverse reactions from post-marketing reports.

The following adverse reactions have been identified during post approval use of Ongentys. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure:

Psychiatric disorders.

Unknown: agitation, psychotic disorder, anxiety, confusional state.

Nervous system disorders.

Unknown: balance disorder, hyperkinesia tremor.

Gastrointestinal disorders.

Common: nausea.
Unknown: diarrhoea.

General disorders and administration site conditions.

Unknown: fatigue, malaise.

Injury, poisoning and procedural complications.

Uncommon: fall.

Reporting of suspected adverse reactions.

Reporting suspected adverse reactions after registration of the medicinal product is important. It allows continued monitoring of the benefit-risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions at www.tga.gov.au/reporting-problems.

4.9 Overdose

There is no known specific antidote. Symptomatic and supportive treatment should be administered as appropriate. Removal of opicapone by gastric lavage and/or inactivation by administering activated charcoal should be considered.
For information on the management of overdose, contact the Poisons Information Centre on 131126 (Australia).

5 Pharmacological Properties

5.1 Pharmacodynamic Properties

ATC code: N04BX04.

Mechanism of action.

Opicapone is a peripheral, selective and reversible catechol-O-methyltransferase (COMT) inhibitor endowed with a high binding affinity (sub-picomolar) that translates into a slow complex dissociation rate constant and a long duration of action (> 24 hours) in vivo.
In the presence of a DOPA decarboxylase inhibitor (DDCI), COMT becomes the major metabolising enzyme for levodopa, catalysing its conversion to 3-O-methyldopa (3-OMD) in the brain and periphery. In patients taking levodopa and a peripheral DDCI, such as carbidopa or benserazide, opicapone increases levodopa plasma levels thereby improving the clinical response to levodopa.

Pharmacodynamic effects.

Opicapone showed a marked (> 90%) and long-lasting (> 24 hours) COMT inhibition in healthy subjects after administration of 50 mg opicapone.
At steady state, in healthy volunteers, following multiple oral administration of immediate-release 100/25 mg levodopa/carbidopa administered three times a day, 10 h after an opicapone 50 mg evening dose the mean extent of levodopa systemic exposure over 24 h (AUC0-24) significantly increased approximately 53% compared to placebo.

Clinical trials.

The efficacy and safety of opicapone has been demonstrated in two Phase 3 double-blind, placebo and active (Study 1 only) controlled studies in 1,027 randomized adult patients with Parkinson's disease treated with levodopa/DDCI (alone or in combination with other antiparkinsonian medicinal products) and end-of-dose motor fluctuations for up to 15 weeks. At screening, the mean age was similar in all treatment groups in both studies, ranging between 61.5 and 65.3 years. Patients had disease severity stages 1 to 3 (modified Hoehn and Yahr) at ON, were treated with 3 to 8 daily doses of levodopa/DDCI and had a daily average OFF-time of at least 1.5 hours. In both studies, 783 patients were randomized with 25 mg or 50 mg of opicapone or placebo. In Study 1, 115 patients were treated with 50 mg of opicapone and 122 patients were treated with 200 mg of entacapone (active comparator). The majority of patients treated in both pivotal studies were treated with immediate-release levodopa/DDCI. There were 60 patients in the combined Phase 3 studies who were predominantly using controlled-release levodopa (i.e. > 50% of their levodopa/DDCI formulations), 48 of whom were treated solely with controlled-release formulations of levodopa. Although there is no evidence that either the efficacy or safety of opicapone would be affected by use of controlled-release levodopa preparations, the experience with such preparations is limited.
Opicapone 50 mg demonstrated clinical efficacy superior to placebo during the double-blind treatment, for the primary efficacy variable used in both pivotal studies, i.e. reduction in OFF-time (Table 2), the proportion of OFF-time responders (i.e. a subject who had a reduction in OFF-time of at least 1 hour from baseline to endpoint) was superior to placebo in Study 2 (Table 3). Except for the proportion of OFF time and ON-time responders in Study 2 all secondary endpoints were exploratory.
The LS mean reduction in absolute OFF-time from baseline to endpoint in the entacapone group was -78.7 minutes. The difference in LS mean change in OFF-time of entacapone to placebo in Study 1 was -30.5 minutes. The difference in LS mean change in OFF-time of opicapone 50 mg to entacapone was -24.8 minutes and non-inferiority of opicapone 50 mg to entacapone was demonstrated (95% confidence interval: -61.4, 11.8).
Most of the gain of ON-time in all treatment groups was ON-time without troublesome dyskinesia. In Study 1, the change from baseline to endpoint in LS mean ON-time without troublesome dyskinesia was 109.1 minutes in the opicapone 50 mg group. The change from baseline for this endpoint in the placebo group was 46.5 minutes. In Study 2, the change from baseline to endpoint in LS mean ON-time without troublesome dyskinesia was 85.6 minutes in the opicapone 50 mg group. The change from baseline for this endpoint in the placebo group was 48.2 minutes.
The results of the open-label (OL) extension studies of 1 year duration in 862 patients who continued treatment from the double-blind studies (Study 1-OL and Study 2-OL) indicated maintenance of the effect achieved during DB study periods. In the OL studies, all patients began at a dose of 25 mg opicapone for the first week (7 days), regardless of their prior treatment in the double-blind period. If end-of-dose motor fluctuations were not sufficiently controlled and tolerability allowed, the opicapone dose could be increased to 50 mg. If unacceptable dopaminergic adverse events were seen, the levodopa dose was to be adjusted. If not sufficient to manage the adverse events, the opicapone dose could then be down titrated.
For other adverse events, the levodopa and/or opicapone dose could be adjusted.

5.2 Pharmacokinetic Properties

Absorption.

Pharmacokinetic results in healthy volunteers showed that opicapone is rapidly absorbed, with a tmax of 0.5 h to 3.0 h following once-daily multiple-dose administration of 50 mg opicapone under fasted conditions.
When a single-dose of 50 mg of opicapone was administered with a high-fat meal, Cmax, AUC0-t, and AUC0-∞ of opicapone significantly decreased around 68%, 53%, and 51%, respectively, in relation to fasted conditions. When a dose of 50 mg of opicapone under steady-state conditions was administered with a moderate-fat meal, Cmax of opicapone also decreased around 62% in relation to fasted conditions. However, no significant effect was observed on the total plasma exposure (AUC0-24), neither in the COMT inhibition profile.

Distribution.

In vitro studies over the opicapone concentration range 0.3 to 30 microgram/mL showed that binding of 14C-opicapone to human plasma proteins is high (99.9%) and concentration-independent. The binding of 14C-opicapone to plasma proteins was unaffected by the presence of warfarin, diazepam, digoxin and tolbutamide, and the binding of 14C-warfarin, 2-14C-diazepam, 3H-digoxin and 14C-tolbutamide was unaffected by the presence of opicapone and opicapone sulfate, the major human metabolite.
After oral administration, the apparent volume of distribution of opicapone at a dose of 50 mg was 29 L with an inter-subject variability of 36%.

Biotransformation.

Sulfation of opicapone is the primary metabolic pathway in humans, yielding an inactive opicapone sulfate metabolite that accounted for 58.6% of the total circulating radioactivity. Other lesser-abundant metabolic pathways include glucuronidation, methylation (by COMT), reduction and glutathione conjugation.

Elimination.

In healthy subjects, the opicapone elimination half-life was 0.7 h to 2.3 h following once-daily multiple-dose administration up to 50 mg opicapone.
Following once-daily multiple oral doses of opicapone in the dose range of 5 to 50 mg, opicapone sulfate presented a long terminal phase with elimination half-life values ranging from 94 h to 114 h and, as a consequence of this long terminal elimination half-life, opicapone sulfate presented a high accumulation ratio in plasma, with values close of up to 6.6.
After oral administration, the apparent total body clearance of opicapone at a dose of 50 mg was 22 L/h, with an inter-subject variability of 45%.
After administration of a single dose of radiolabeled opicapone 100 mg (2 times the recommended dosage) to healthy subjects, approximately 70% of the dose was recovered in feces (22% as unchanged), 20% in expired air, and 5% in urine (< 1% as unchanged).

Linearity/non-linearity.

Opicapone exposure was shown to increase in a dose proportional manner following once-daily multiple dose administration only up to 50 mg opicapone.

Elderly (≥ 65 years old).

The pharmacokinetics of opicapone was evaluated in elderly subjects (aged 65-78 years old) after 7-day multiple-dose administration of 30 mg. An increase in both the peak and extent of systemic exposure was observed for the elderly population when compared to the young population. The S-COMT activity inhibition was significantly increased in elderly subjects. The magnitude of this effect is not considered to be of clinical relevance.

Weight.

There is no relationship between exposure of opicapone and body weight over the range of 40-100 kg.

Hepatic impairment.

There is limited clinical experience in patients with moderate hepatic impairment (Child-Pugh Class B). The pharmacokinetics of opicapone was evaluated in healthy subjects and moderate chronic hepatic impaired patients after administration of a single dose of 50 mg. The bioavailability of opicapone was significantly higher in patients with moderate chronic hepatic impairment (Cmax = 1038 nanogram/mL vs 548 nanogram/mL in healthy subjects; ASC0-t = 3120 nanogram.h/mL vs. 1668 nanogram.h/mL in healthy subjects).
There is no clinical experience in patients with mild hepatic impairment (Child-Pugh Class A) and in patients with severe hepatic impairment (Child-Pugh Class C) (see Section 4.2 Dose and Method of Administration).

Renal impairment.

The pharmacokinetics of opicapone was not directly evaluated in subjects with chronic renal impairment. However, an evaluation with 50 mg opicapone was performed in subjects included in both phase 3 studies with GFR/1.73 m2 < 60 mL/min (i.e. moderately decreased renal elimination capacity), and using pooled BIA 9-1103 data (major metabolite of opicapone). BIA 9-1103 plasma levels were not affected in patients with chronic renal impairment, and as such, no dose adjustment needs to be considered.

5.3 Preclinical Safety Data

Genotoxicity.

Opicapone was not mutagenic in an in vitro bacterial reverse mutation (Ames) assay, chromosome aberration test in vitro and in vivo rat micronucleus test.

Carcinogenicity.

Two-year oral carcinogenicity studies at doses up to 750 or 1000 mg/kg/day in mice and rats respectively (approximately 4 or 10 times the clinical exposure based on AUC) showed no clear evidence of carcinogenicity.

6 Pharmaceutical Particulars

6.1 List of Excipients

Capsule content.

Lactose monohydrate, sodium starch glycollate type A, pregelatinised maize starch, magnesium stearate.

Capsule shell.

Gelatin, indigo carmine aluminium lake, erythrosine, titanium dioxide.

Printing ink.

Shellac, titanium dioxide, propylene glycol, ammonia solution (concentrated), simethicone.

6.2 Incompatibilities

Not applicable.

6.3 Shelf Life

In Australia, information on the shelf life can be found on the public summary of the Australian Register of Therapeutic Goods (ARTG). The expiry date can be found on the packaging.

6.4 Special Precautions for Storage

Store below 30°C.
Store in the original package to protect from moisture.

6.5 Nature and Contents of Container

Opicapone 50 mg hard capsule is packaged in OPA/AL/PVC/Al blisters containing 10, 30 or 90 capsules.
Not all pack sizes may be marketed.

6.6 Special Precautions for Disposal

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

6.7 Physicochemical Properties

Chemical structure.


CAS number.

923287-50-7.

7 Medicine Schedule (Poisons Standard)

Schedule 4.

Summary Table of Changes